ECM Weekly (11th June 2023) - Alibaba, Tencent, PDD, Redox, Amman, Kotak, Infratil, Skymark
Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
510 Views
Kelun-Biotech (科伦博泰) Pre-IPO: Thoughts on Valuation
Kelun Biotech is raising up to US$400m to list in Hong Kong. In this note we provide valuation for its core products, SKB264 and A166.
614 Views
China Healthcare Weekly (Apr.28) - Four Stages of China Biotech, The Real Foothold of R&D, Kelun
The real foothold of pharmaceutical company is “Development” rather than “Research”. China biotech will go through four stages: 2015-2019, 2019...
526 Views
Pre-IPO Kelun Biotech - Debut Is the Peak, and Then It Wanes?
After out-licensing all valuable core assets to Merck, Kelun-Biotech's remaining pipeline has limited value. As core R&D team have left, the lack...
519 Views